Cargando…

A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model

Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and targets multiple receptor tyrosine kinases. However, sorafenib only extends the average survival time by 3 months. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chuang, Hui-Yen, Tyan, Yeu-Sheng, Hwang, Jeng-Jong, Shih, Kuang-Chung, Lin, Wei-Chan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933744/ https://www.ncbi.nlm.nih.gov/pubmed/33692869 http://dx.doi.org/10.3892/ol.2021.12598

Ejemplares similares

Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model
por: Chen, John Chun-Hao, et al.
Publicado: (2016)

Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model
por: Tyan, Yeu-Sheng, et al.
Publicado: (2021)

Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB Pathway
por: Chuang, Hui-Yen, et al.
Publicado: (2019)

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
por: You, Abin, et al.
Publicado: (2016)

Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study
por: Teng, Chieh-Lin, et al.
Publicado: (2012)

Establishment of image‐guided radiotherapy of orthotopic hepatocellular carcinoma mouse model
por: Zhou, Kaixiao, et al.
Publicado: (2023)

Liposomal β-Sitosterol Suppresses Metastasis of CT26/luc Colon Carcinoma via Inhibition of MMP-9 and Evoke of Immune System
por: Shen, Chao-Yu, et al.
Publicado: (2022)

Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
por: Yoo, Eun Jin, et al.
Publicado: (2013)

Curcumin Sensitizes Hepatocellular Carcinoma Cells to Radiation via Suppression of Radiation-Induced NF-κB Activity
por: Hsu, Fei-Ting, et al.
Publicado: (2015)

Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism
por: Shueng, Pei-Wei, et al.
Publicado: (2022)

Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis
por: Liu, Chieh-Min, et al.
Publicado: (2021)

Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma
por: Cha, Jihye, et al.
Publicado: (2013)

Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
por: Chuang, Hui-Yen, et al.
Publicado: (2014)

Image-guided radiotherapy in an orthotopic mouse model of rectal cancer
por: Nicolas, Adele M., et al.
Publicado: (2022)

Beneficial Effect of Combining Radiotherapy and Transarterial Chemoembolization on Patient Survival in Hepatocellular Carcinomas and Macrovascular Invasion Treated with Sorafenib
por: Lu, Meng-Chuan, et al.
Publicado: (2023)

CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5‐LSD1‐NF‐κB oncogenic signaling
por: Hu, Bo, et al.
Publicado: (2020)

Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
por: Chu, Shou-Sheng, et al.
Publicado: (2021)

Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

An Orthotopic Implantation Mouse Model of Hepatocellular Carcinoma with Underlying Liver Steatosis
por: Kasashima, Hiroaki, et al.
Publicado: (2020)

Synergistic Effect of Ginsenoside Rh2 Combines with Ionizing Radiation on CT26/luc Colon Carcinoma Cells and Tumor-Bearing Animal Model
por: Lee, Shan-Chih, et al.
Publicado: (2023)

Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy
por: Kuo, Yu-Cheng, et al.
Publicado: (2011)

Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
por: Teng, Chiao-Fang, et al.
Publicado: (2021)

Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma
por: Huang, Yao-Kuang, et al.
Publicado: (2017)

Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy
por: Hage, Carina, et al.
Publicado: (2019)

Ultrasound-Guided Approaches to Improve Orthotopic Mouse Xenograft Models for Hepatocellular Carcinoma
por: About, Ghina Bou, et al.
Publicado: (2019)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Osthole attenuates angiogenesis in an orthotopic mouse model of hepatocellular carcinoma via the downregulation of nuclear factor-κB and vascular endothelial growth factor
por: Yao, Fei, et al.
Publicado: (2018)

The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Wada, Yoshiyuki, et al.
Publicado: (2017)

Is the Concurrent Use of Sorafenib and External Radiotherapy Feasible for Advanced Hepatocellular Carcinoma? A Meta-Analysis
por: Rim, Chai Hong, et al.
Publicado: (2021)

Establishment of linear accelerator-based image guided radiotherapy for orthotopic 4T1 mouse mammary tumor model
por: Lee, Seung-Heon, et al.
Publicado: (2014)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

A Yes-Associated Protein (YAP) and Insulin-Like Growth Factor 1 Receptor (IGF-1R) Signaling Loop Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma
por: Ngo, Mai-Huong T., et al.
Publicado: (2021)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Abulimiti, Munire, et al.
Publicado: (2021)

Combination treatment of transcatheter arterial chemoembolization, intensity-modulated radiotherapy, and sorafenib for hepatocellular carcinoma with macrovascular invasion
por: Yang, Dan, et al.
Publicado: (2023)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ggqup82rjulvpnveiefqbridj6